Literature DB >> 16794395

High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis.

Philippe Esquis1, David Consolo, Guy Magnin, Philippe Pointaire, Philippe Moretto, Maria Dolores Ynsa, Jean-Luc Beltramo, Carole Drogoul, Michel Simonet, Laurent Benoit, Patrick Rat, Bruno Chauffert.   

Abstract

OBJECTIVE: To investigate the role of increased intra-abdominal pressure (IAP) on the intratumoral accumulation and the antitumor effect of intraperitoneal cisplatin in rats with advanced peritoneal carcinomatosis. To evaluate the tolerance of IAP in pigs, as it is a large animal with a body size equivalent to humans. SUMMARY BACKGROUND DATA: To investigate if an active convection, driven by a positive IAP, increases cisplatin penetration and antitumor effectiveness in a model of advanced peritoneal carcinomatosis in rats. EXPERIMENTAL
DESIGN: BDIX rats with macroscopic peritoneal tumors received cisplatin administered as intravenous injection (IV), conventional intraperitoneal injection (IP), or sustained intraperitoneal injection of cisplatin given in a large volume of solvent for maintaining IAP for 1 hour. Platinum tissue concentration was measured by atomic absorption spectroscopy (AAS), and platinum distribution into the tumor nodules was assessed by the particular-induced x-ray emission (PIXE) method. The antitumor effect was assessed in a survival experiment. The hemodynamic, local, and systemic tolerance of IAP, with or without cisplatin, was evaluated in Large White pigs.
RESULTS: The maximum tolerated IAP was 22 mm Hg for 1 hour in nonventilated rats. IAP, in comparison with IV or conventional IP injections, resulted in the increased concentration and depth of diffusion of platinum into diaphragm and peritoneal tumor nodules. Consequently, IAP treatment induced an extended survival of rats treated at an advanced stage of carcinomatosis. In 7 50- to 70-kg ventilated pigs, a 40-mm Hg IAP was well tolerated when maintained stable for 2 hours. Renal failure occurred in pigs receiving a total dose of 200 and 400 mg of cisplatin with IAP, but a dose of 100 mg was well tolerated.
CONCLUSIONS: Intraperitoneal chemotherapy with increased IAP, in comparison with conventional IP or IV chemotherapy, improved the tumor accumulation and the antitumor effect of cisplatin in rats bearing advanced peritoneal carcinomatosis. In preclinical conditions, the tolerance of sustained IAP was manageable in ventilated pigs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794395      PMCID: PMC1570583          DOI: 10.1097/01.sla.0000218089.61635.5f

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  33 in total

1.  Carcinomatosis--is cure an option?

Authors:  Paul H Sugarbaker
Journal:  J Clin Oncol       Date:  2003-03-01       Impact factor: 44.544

2.  Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy.

Authors:  M J Piccart; A Floquet; G Scarfone; P H B Willemse; J Emerich; I Vergote; L Giurgea; C Coens; A Awada; J B Vermorken
Journal:  Int J Gynecol Cancer       Date:  2003 Nov-Dec       Impact factor: 3.437

3.  Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis.

Authors:  P Favoulet; G Magnin; J C Guilland; J L Beltramo; L Osmak; L Benoit; P Rat; S Douvier; C Duvillard; B Chauffert
Journal:  Eur J Surg Oncol       Date:  2001-02       Impact factor: 4.424

4.  Convection enhanced delivery for the treatment of malignant gliomas: symposium review.

Authors:  Michael A Vogelbaum
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

5.  Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.

Authors:  Patrick Favoulet; Laurent Benoit; Liliana Osmak; Emmanuel Polycarpe; Philippe Esquis; Christian Duvillard; Boris Guiu; Patrick Rat; Jean Pierre Favre; Bruno Chauffert
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

Review 6.  Intraperitoneal antineoplastic drug delivery: rationale and results.

Authors:  Maurie Markman
Journal:  Lancet Oncol       Date:  2003-05       Impact factor: 41.316

7.  Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

8.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

Review 9.  Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives.

Authors:  Bruno Chauffert; Patrick Favoulet; Emmanuel Polycarpe; Christian Duvillard; Jean-Luc Beltramo; Francis Bichat; Patrick Rat; Philippe Genne; Laurent Benoit
Journal:  Surg Oncol Clin N Am       Date:  2003-07       Impact factor: 3.495

Review 10.  Primary ovarian cancer chemotherapy: current standards of care.

Authors:  W P McGuire; M Markman
Journal:  Br J Cancer       Date:  2003-12       Impact factor: 7.640

View more
  52 in total

1.  Administration of substances to laboratory animals: routes of administration and factors to consider.

Authors:  Patricia V Turner; Thea Brabb; Cynthia Pekow; Mary Ann Vasbinder
Journal:  J Am Assoc Lab Anim Sci       Date:  2011-09       Impact factor: 1.232

2.  Appraisal of peritoneal cavity's capacity in order to assess the pharmacology of liquid chemotherapy solution in hyperthermic intraperitoneal chemotherapy.

Authors:  Alexis Duez; Eddy Cotte; Olivier Glehen; François Cotton; Naoual Bakrin
Journal:  Surg Radiol Anat       Date:  2009-03-19       Impact factor: 1.246

Review 3.  Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey.

Authors:  M Graversen; S Detlefsen; P Pfeiffer; L Lundell; M B Mortensen
Journal:  Clin Exp Metastasis       Date:  2018-04-28       Impact factor: 5.150

4.  Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the surgical team to chemotherapy drugs.

Authors:  Laurent Benoit; Nicolas Cheynel; Pablo Ortega-Deballon; Giovanni Di Giacomo; Bruno Chauffert; Patrick Rat
Journal:  Ann Surg Oncol       Date:  2007-10-10       Impact factor: 5.344

Review 5.  Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview.

Authors:  Miguel Alberto; Andreas Brandl; Pankaj Kumar Garg; Safak Gül-Klein; Mathias Dahlmann; Ulrike Stein; Beate Rau
Journal:  Clin Exp Metastasis       Date:  2019-02-04       Impact factor: 5.150

Review 6.  Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review.

Authors:  Clemens B Tempfer; Wiebke Solass; Marc-André Reymond
Journal:  Wien Med Wochenschr       Date:  2014-09-24

7.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer.

Authors:  Philipp Horvath; Stefan Beckert; Florian Struller; Alfred Königsrainer; Marc André Reymond
Journal:  Clin Exp Metastasis       Date:  2018-07-30       Impact factor: 5.150

8.  Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: a descriptive cohort study.

Authors:  S Bremholm Ellebæk; M Graversen; S Detlefsen; L Lundell; C W Fristrup; P Pfeiffer; M B Mortensen
Journal:  Clin Exp Metastasis       Date:  2020-01-30       Impact factor: 5.150

Review 9.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

Authors:  Wim P Ceelen; Michael F Flessner
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

Review 10.  Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy.

Authors:  Kurt Van der Speeten; Oswald Anthony Stuart; Paul H Sugarbaker
Journal:  Curr Drug Discov Technol       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.